American Journal of Medical Case Reports
ISSN (Print): 2374-2151 ISSN (Online): 2374-216X Website: http://www.sciepub.com/journal/ajmcr Editor-in-chief: Samy, I. McFarlane
Open Access
Journal Browser
Go
American Journal of Medical Case Reports. 2016, 4(12), 389-392
DOI: 10.12691/ajmcr-4-12-5
Open AccessCase Report

Protein-losing Enteropathy in Association with Right Heart Failure

Takanobu Hirosawa1, Kazuhito Hirata1, and Wake Minoru2

1Division of Internal Medicine, Okinawa Chubu Hospital, 281 Miyazato, Uruma, Okinawa, Japan

2Division of Cardiology, Okinawa Chubu Hospital, 281 Miyazato, Uruma, Okinawa, Japan

Pub. Date: December 30, 2016

Cite this paper:
Takanobu Hirosawa, Kazuhito Hirata and Wake Minoru. Protein-losing Enteropathy in Association with Right Heart Failure. American Journal of Medical Case Reports. 2016; 4(12):389-392. doi: 10.12691/ajmcr-4-12-5

Abstract

A 65-year-old woman, with past history of mitral valve replacement, developed severe right heart failure. In addition to elevated right heart pressure, she had significant hypoalbuminemia as the important cause of refractory edema. Technetium-99m-labelled human serum albumin scintigraphy showed leak of protein from the transverse colon and the excretion of alpha 1 antitrypsin in the stool was markedly increased. Diagnosis of protein losing enteropathy was established. The etiology was increased lymphatic pressure secondary to right heart failure of multifactorial cause, including elevated left side filling pressures and out of proportion pulmonary hypertension due to old tuberculosis, resulting in significant tricuspid regurgitation. The patient was managed conservatively with increased dose of furosemide from 10-20mg every other day up to 40-60mg/day, and maximum dose of tolvaptan (a vasopressin 2 receptor blocker) of 15mg/ day, in addition to high protein diet.

Keywords:
protein losing enteropathy right heart failure tolvaptan

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Umar SB, DiBaise JK. Protein-losing enteropathy: case illustrations and clinical review. Am J Gastroenterol 2010; 105: 43-49.
 
[2]  Davidson JD, Waldmann TA, Goodman DS, Gordon RSJr. Protein-losing gastroenteropathy in congestive heart failure. Lancet 1961; 1: 899-902.
 
[3]  Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE Study Group. J Thorac Cardiovasc Surg 1998; 115: 1063-1073.
 
[4]  Wilkinson P, Pinto B, Senior JR. Reversible protein-losing enteropathy with intestinal lymphangiectasia secondary to chronic constrictive pericarditis. N Engl J Med. 1965; 273: 1178-1181.
 
[5]  Müller C, Globits S, Glogar D, Klepetko W, Knoflach P. Constrictive pericarditis without typical haemodynamic changes as a cause of oedema formation due to protein-losing enteropathy. Eur Heart J. 1991 12: 1140-1143.
 
[6]  Strober W, Cohen LS, Waldmann TA, Braunwald E. Tricuspid regurgitation. A newly recognized cause of protein-losing enteropathy, lymphocytopenia and immunologic deficiency. Am J Med 1968; 44: 842-850.
 
[7]  Strygler B, Nicor MJ, Santangelo WC, Porter JL, Fordtran JS. α1-antitrypsin excretion in stool in normal subjects and in patients with gastrointestinal disorders. Gastroenterology 1990; 99: 1380-1387.
 
[8]  Divgi CR, Lisann NM, Yesh SD, Benua RS. Technetium-99m albumin scintigraphy in the diagnosis of protein-losing enteropathy. J Nucl Med 1986; 27: 1710-1712.
 
[9]  Gerges C, Gerges M, Lang MB et al. Diastolic pulmonary vascular pressure gradient: A Predictor of prognosis in “out-of-proportion” pulmonary hypertension. CHEST 2013; 143: 758-766.
 
[10]  Onishi T, Idei Y, Otsui K et al. Coconut atrium in long-standing rheumatic valvular heart disease. Am J Case Rep. 2015; 16: 191-195.
 
[11]  Felker GM, Mentz RJ, Adams KF et al. Tolvaptan in patients hospitalized with acute heart failure rationale and design of the TACTICS and the SECRET of CHF Trials. Circulation: Heart Failure. 2015; 8: 997-1005.